Overview / Abstract: |
STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years. TARGET AUDIENCE Medical oncologists, radiation oncologists, urologists, and other health care professionals involved in the treatment of patients with prostate cancer. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1.) Evaluate recent efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant nonmetastatic prostate cancer |
Expiration |
Jun 04, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Live / Seminar, Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 CME |
Accreditation |
ACCME |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
Judd W. Moul, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Sanofi. |
Keywords / Search Terms |
i3 Health i3 Health i3 Health, prostate cancer, online CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD CME, Live CE CME Seminar CE CME Free CE CME Live CE CME Seminar CE CME |
LIVE Activity Location Details |
Date(s)
i3 Health |